Publication:
Factors influencing response and remission in the treatment of major depressive disorder: Can social adaptation be a determinant factor?

dc.contributor.buuauthorSivrioğlu, Yusuf
dc.contributor.buuauthorKırlı, Selçuk
dc.contributor.buuauthorAkkaya, Cengiz
dc.contributor.buuauthorEker, Salih Saygın
dc.contributor.buuauthorÖzkaya, Güven
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentPsikiyatri Ana Bilim Dalı
dc.contributor.departmentBiyoistatistik Ana Bilim Dalı
dc.contributor.orcid0000-0003-0297-846X
dc.contributor.researcheridQ-9477-2019
dc.contributor.researcheridA-4421-2016
dc.contributor.scopusid14062563200
dc.contributor.scopusid14019745700
dc.contributor.scopusid14061855100
dc.contributor.scopusid14019347700
dc.contributor.scopusid16316866500
dc.date.accessioned2022-04-26T08:56:32Z
dc.date.available2022-04-26T08:56:32Z
dc.date.issued2009-03
dc.description.abstractObjective: Major depression is a frequent disorder successfully treated with antidepressants (1). Response and remission depend on the type of pharmacological treatment as well as patient characteristics. The aim of the study is to evaluate the factors influencing response and remission rates. Method: Data from 4 studies (2-4) sharing the same methodology is pooled and reanalyzed. Subjects with major depression were assigned to reboxetine, sertraline or venlafaxine XR treatment in an open label fashion. The initial dose of reboxetine and venlafaxine XR were 4mg/day and 75mg/day respectively. The dose was increased at the second week to 8mg/day for reboxetine and 150mg/day for venlafaxine XR. Sertraline dose was 50mg/day throughout the study. Subjects were assessed at baseline, 2 weeks, 4 weeks, 7 weeks and 10 weeks with Hamilton Depression Rating Scale (HDRS) (5), Hamilton Anxiety Rating Scale (HARS) (6) and, Social Adaptation Self-Evaluation Scale (SASS) (7). Results: Characteristics of the study population (n=149) are summarized in Table 1. The response and remission rates were 67.8% (n=101) and 55% (n=82) respectively. Total number of episodes, time since first episode, baseline HDRS and HARS scores were significantly lower and baseline SASS score was significantly higher in responders and remitters when compared to non-responders and non-remitters respectively (Table 2). Logistic regression analyses where response and remission were dependent variables and, treatment arm, gender, age, duration of last episode, number of past episodes,.time since first episode and baseline HDRS, HADRS and SASS scores were independent variables revealed that baseline SASS score was the only factor significantly increasing the odds of response (p=0.035 OR:1.06 %95 CI: 1.005-1.131) and remission (p=0,019 OR:1,07 %95CI: 1,012-1,140). Conclusion: Our findings suggest that baseline social adaptation may have a modest impact on response and remission but other factors not evaluated in our study may also influence the rates of response and remission.
dc.identifier.citationSivrioğlu, Y. vd. (2009). "Factors influencing response and remission in the treatment of major depressive disorder: Can social adaptation be a determinant factor?". Klinik Psikofarmakoloji Bülteni, 19(Supplement 1), S137-S139.
dc.identifier.endpageS139
dc.identifier.issn1017-7833
dc.identifier.issueSupplement 1
dc.identifier.scopus2-s2.0-67650763146
dc.identifier.startpageS137
dc.identifier.urihttp://hdl.handle.net/11452/26087
dc.identifier.volume19
dc.identifier.wos000209020900036
dc.indexed.wosSCIE
dc.language.isotr
dc.publisherKüre İletişim
dc.relation.journalKlinik Psikofarmakoloji Bülteni
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMajor depression
dc.subjectPharmacotherapy
dc.subjectReboxetine
dc.subjectRemission
dc.subjectReply
dc.subjectSertraline
dc.subjectSocial adaptation
dc.subjectVenlafaxine
dc.subjectReboxetine
dc.subjectEfficacy
dc.subjectTolerability
dc.subjectVenlafaxine
dc.subjectSertraline
dc.subjectPharmacology & pharmacy
dc.subjectPsychiatry
dc.subject.emtreeReboxetine
dc.subject.emtreeSertraline
dc.subject.emtreeVenlafaxine
dc.subject.emtreeAdult
dc.subject.emtreeConference paper
dc.subject.emtreeControlled study
dc.subject.emtreeDrug dose increase
dc.subject.emtreeFollow up
dc.subject.emtreeGender
dc.subject.emtreeGroups by age
dc.subject.emtreeHamilton Anxiety Scale
dc.subject.emtreeHamilton scale
dc.subject.emtreeHuman
dc.subject.emtreeLogistic regression analysis
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMajor depression
dc.subject.emtreeOpen study
dc.subject.emtreePsychologic assessment
dc.subject.emtreePsychopharmacotherapy
dc.subject.emtreeRating scale
dc.subject.emtreeRemission
dc.subject.emtreeSelf evaluation
dc.subject.emtreeSocial adaptation
dc.subject.emtreeTreatment response
dc.subject.scopusMorpholines; Reboxetine; Amino Alcohols
dc.subject.wosPharmacology & pharmacy
dc.subject.wosPsychiatry
dc.titleFactors influencing response and remission in the treatment of major depressive disorder: Can social adaptation be a determinant factor?
dc.title.alternativeMajör depresif bozukluk tedavisinde yanıt ve remisyona etki eden faktörler: Sosyal uyum belirleyici olabilir mi?
dc.typeArticle
dc.wos.quartileQ4
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Psikiyatri Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Biyoistatistik Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: